索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]王芳,钟光珍,于丽平.心血管疾病风险评估的发展及现状[J].国际心血管病杂志,2016,06:337-340.
点击复制

心血管疾病风险评估的发展及现状(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2016年06期
页码:
337-340
栏目:
综述
出版日期:
2016-11-20

文章信息/Info

Title:
-
作者:
王芳; 钟光珍; 于丽平
100020 首都医科大学附属北京朝阳医院心脏中心
Author(s):
-
关键词:
心血管疾病; 风险评估; 危险因素; 一级预防
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2016.06.005
文献标识码:
-
摘要:
心血管疾病风险评估是早期识别高危人群、进行积极干预、提高一级预防效果的有效手段。近半个世纪以来,国内外先后发布了多种心血管疾病风险评估工具,该文介绍临床常用的几种心血管疾病风险评估工具,为临床医生提供参考。
Abstract:
-

参考文献/References

[1] 陈伟伟,高润霖,刘力生,等.《中国心血管病报告2014》概要[J]. 中国循环杂志, 2015,30(7):617-622.
[2] Truett J, Cornfield J, Kannel W. A multivariate analysis of the risk of coronary heart disease in Framingham[J]. J Chronic Dis, 1967, 20(7): 511-524.
[3] Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile. A statement for health professionals[J]. Circulation, 1991, 83(1): 356-362.
[4] Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories[J]. Circulation, 1998, 97(18): 1837-1847.
[5] Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program(NCEP)expert panel on detection, evaluation, and treatment of high blood cholesterol in adults(Adult Treatment Panel Ⅲ)[J]. JAMA, 2001, 285(19): 2486-2497.
[6] Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the reynolds risk score[J]. JAMA, 2007, 297(6): 611-619.
[7] Ridker PM, Paynter NP, Rifai N, et al.C-reactive protein and parental history improve global cardiovascular risk prediction: the reynolds risk score for men[J]. Circulation, 2008, 118(22): 2243-2251.
[8] DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort[J]. Ann Intern Med, 2015, 162(4): 266-275.
[9] D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study[J]. Circulation, 2008, 117(6):743-753.
[10] Cook NR, Paynter NP, Eaton CB, et al. Comparison of the framingham and reynolds risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative[J]. Circulation, 2012, 125(14): 1748-1756, S1-S11.
[11] Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2014, 63(25 Pt B): 2935-2959.
[12] Fried LP, Borhani NO, Enright P, et al. The cardiovascular health study: design and rationale[J]. Ann Epidemiol, 1991, 1(3): 263-276.
[13] Friedman GD, Cutter GR, Donahue RP, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects[J]. J ClinEpidemiol, 1988, 41(11):1105-1116.
[14] The Atherosclerosis Risk in Communities(ARIC)Study: design and objectives. The ARIC investigators [J]. Am J Epidemiol, 1989, 129(4): 687-702.
[15] Amin NP, Martin SS, Blaha MJ, et al. Headed in the right direction but at risk for miscalculation: a critical appraisal of the 2013 ACC/AHA risk assessment guidelines[J]. J Am Coll Cardiol, 2014, 63(25 PtA): 2789-2794.
[16] Conroy RM, PyöräläK, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project[J]. Eur Heart J, 2003, 24(11): 987-1003.
[17] Graham I, Atar D, Borch-Johnsen K, et al.European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice(constituted by representatives of nine societies and by invited experts)[J]. Eur J Cardiovasc Prev Rehabil, 2007, 14(Suppl 2): S1-113.
[18] European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology(ESC)and the European Atherosclerosis Society(EAS)[J]. Eur Heart J, 2011, 32(14): 1769-1818.
[19] Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study[J]. BMJ, 2007, 335(7611): 136.
[20] Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2[J]. BMJ, 2008, 336(7659): 1475-1482.
[21] National Institute for Health and care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification[DB/OL]. http://www.nice.org.uk/guidance /cg181,2016-07.
[22] World Health Organization.Prevention of cardiovascular disease. Guidelines for assessment and management of cardiovascular risk[M]. WHO Press, 2007.
[23] 王 薇, 赵 冬, 刘 静, 等. 中国35～64岁人群心血管病危险因素与发病危险预测模型的前瞻性研究[J]. 中华心血管病杂志, 2003, 31(12): 902-908.
[24] Liu J, Hong Y, D'Agostino RB Sr, et al. Predictive value for the chinese population of the framingham CHD risk assessment tool compared with the chinese multi-provincial cohort study[J]. JAMA, 2004, 291(21): 2591-2599.
[25] 国家“十五”攻关“冠心病、脑卒中综合危险度评估及干预方案的研究”课题组.国人缺血性心血管病发病危险的评估方法及简易评估工具的开发研究[J].中华心血管病杂志, 2003, 31(12):893-901.
[26] Wu Y, Liu X, Li X, et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults[J]. Circulation, 2006, 114(21):2217-2225.
[27] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 中国心血管病预防指南[J]. 中华心血管病杂志, 2011, 39(1): 3-22.

备注/Memo

备注/Memo:
通信作者:于丽平, Email:yhp@medmail.com.cn
更新日期/Last Update: 2016-11-20